Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

241.74 -1.51 (-0.62%)
Streaming Delayed Price Updated: 12:34 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... 
Via Benzinga
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M... 
Via Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Expert Ratings For Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed... 
Via Benzinga
10 Biggest Price Target Changes For Monday
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan
Novo Nordisk is buying an RNA interference company. 
Via Investor's Business Daily
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra... 
Via Benzinga
Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript
ALNY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO. 
Via The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.